ArticleFrontiers in public health2025
Musculoskeletal adverse events reported post-hepatitis B vaccination in the vaccine adverse event reporting system.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatitis B virus (HBV) is a major cause of chronic liver disease. While the hepatitis B vaccine has been proven effective in preventing HBV infection, concerns regarding Events Supposedly Attributable to Vaccination or Immunization (ESAVI) persist. This study aims to utilize the Vaccine Adverse Event Reporting System (VAERS) database to explore potential associations between the hepatitis B vaccine and musculoskeletal system AEs, providing a scientific basis for vaccine safety evaluations. Methods: This study analyzed VAERS data from 1990 to 2024, focusing on 76,887 reports associated with hepatitis B vaccines. Disproportionality analysis methods, such as the Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR), were applied to identify the distribution and signal strength of musculoskeletal-related AEs. Furthermore, multivariable logistic regression analysis was conducted to explore association between patients with HBV vaccine and death. Results: Musculoskeletal system ESAVIs constituted a significant portion of all reports, including tendon fibrosis (ROR = 251.82), myofascitis (ROR = 107.51), fasciitis (ROR = 71.52), and osteoarthritis (ROR = 7.56). Tendon fibrosis demonstrated the strongest association, potentially linked to chronic inflammatory responses and abnormal tissue repair induced by aluminum adjuvants. Most AEs occurred within 30 days post-vaccination, though some, such as myofascitis, had a longer mean onset time (1,671 days), reflecting the slow-release properties of aluminum adjuvants. In multivariable logistic regression analysis, we concluded that male and combination vaccine treatment were risk factors while age from18-64 years was a protective factors of death. Conclusion: This study identifies potential associations between hepatitis B vaccination and musculoskeletal system AEs, emphasizing the need for thorough pre-vaccination assessments and post-vaccination monitoring for high-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.